Oncolytic viruses get a boost with first FDA-approval recommendation
Elie Dolgin • June 1, 2015
The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies.
Continue reading here.
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.